Overview

Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease

Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and Efficacy of donepezil in treatment of AD patients in China.
Phase:
Phase 4
Details
Lead Sponsor:
Beijing Friendship Hospital
Collaborators:
Eisai China Inc.
Xuanwu Hospital, Beijing
Treatments:
Donepezil